{"id":389907,"date":"2021-12-30T00:00:00","date_gmt":"2021-12-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0004-2021-biopharma-malignant-melanoma-disease-landscape-forecast-g7-2021\/"},"modified":"2026-03-31T10:41:19","modified_gmt":"2026-03-31T10:41:19","slug":"dlsfon0004-2021-biopharma-malignant-melanoma-disease-landscape-forecast-g7-2021","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0004-2021-biopharma-malignant-melanoma-disease-landscape-forecast-g7-2021\/","title":{"rendered":"Malignant Melanoma | Disease Landscape &#038; Forecast | G7 | 2021"},"content":{"rendered":"<p>The introduction of immune checkpoint inhibitors Keytruda (Merck &#038; Co.), Opdivo \u00b1 Yervoy (Bristol Myers Squibb), and Tecentriq (Roche \/ Genentech; United States only), as well as\u00a0BRAF\/MEK\u00a0inhibitor combinations, such as Roche \/ Genentech\u2019s Zelboraf + Cotellic, Novartis\u2019s Tafinlar + Mekinist, and Pfizer \/ Array BioPharma\u2019s Braftovi + Mektovi, has significantly changed the treatment landscape for malignant melanoma in both the resectable and metastatic settings. Nonetheless, opportunities remain for novel agents specifically targeting the underrepresented\u00a0<em>BRAF<\/em>\u00a0wild-type unresectable or metastatic population. With the expected introduction of novel agents and combination regimens, the malignant melanoma treatment paradigm will continue to evolve. In such a dynamic indication, marketed drugs need to be carefully positioned to achieve optimal uptake.<\/p>\n<p><strong>Questions Answered:<\/strong><\/p>\n<ul>\n<li>How large are the clinically and commercially relevant malignant melanoma drug-treatable populations? Will drug-treatment rates increase over the forecast period?<\/li>\n<li>What is the current treatment landscape in malignant melanoma? Which currently approved drugs are the most important and why?<\/li>\n<li>Which drugs in late-phase development are poised to change the treatment landscape for malignant melanoma and how? What sales \/ uptake could these drugs secure in the malignant melanoma market?<\/li>\n<li>What are the key drivers and constraints in the malignant melanoma market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content Highlights<\/strong><\/p>\n<p>Geographies: United States,\u00a0EU5, Japan.<\/p>\n<p>Primary research: 19 country-specific interviews with thought-leading medical oncologists, supported by survey data collected for this and other Clarivate research.<\/p>\n<p>Epidemiology: Diagnosed incidence of malignant melanoma by country, segmented by disease stage and\u00a0<em>BRAF<\/em>\u00a0mutation status.<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key malignant melanoma therapies through 2029, segmented by brands \/ generics and epidemiological subpopulations.<\/p>\n<p>Emerging therapies: Phase III: 10 drugs; Phase II: 7 drugs.<\/p>\n<p><strong>Product Description<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em>\u00a0provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution Enhancement<\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast\u00a0<\/em>will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-389907","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-malignant-melanoma","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389907\/revisions"}],"predecessor-version":[{"id":576287,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389907\/revisions\/576287"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}